Who are AK117's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SCTB14, SHR-1314, KI1106 4g, QD, Treatment Choice (TC), CHS-1420, MB-102 DMID.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ak117.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

AK117 — Competitive Intelligence Brief

AK117 (AK117) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD47/SIRPα axis inhibitor. Area: Oncology.

phase 2 CD47/SIRPα axis inhibitor CD47 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

AK117 (AK117) — Akeso. AK117 is a small molecule targeting the CD47/SIRPα axis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AK117 TARGET	AK117	Akeso	phase 2	CD47/SIRPα axis inhibitor	CD47
SCTB14	SCTB14	Sinocelltech Ltd.	phase 3	CD47/SIRPα axis inhibitor	CD47/SIRPα axis
SHR-1314	SHR-1314	Jiangsu HengRui Medicine Co., Ltd.	phase 3	CD47/SIRPα inhibitor	CD47/SIRPα axis
KI1106 4g, QD	KI1106 4g, QD	Kuhnil Pharmaceutical Co., Ltd.	phase 3	CD47/SIRPα inhibitor	CD47/SIRPα axis
Treatment Choice (TC)	Treatment Choice (TC)	Astex Pharmaceuticals, Inc.	phase 3	SIRPα inhibitor	CD47
CHS-1420	CHS-1420	Coherus Oncology, Inc.	phase 3	Bispecific antibody	CD47 and CD40
MB-102 DMID	MB-102 DMID	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	phase 3	monoclonal antibody	CD47

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CD47/SIRPα axis inhibitor class)

Akeso · 1 drug in this class
AltruBio Inc. · 1 drug in this class
Bristol-Myers Squibb · 1 drug in this class
City of Hope Medical Center · 1 drug in this class
Cloudbreak Therapeutics, LLC · 1 drug in this class
Sinocelltech Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AK117 — Competitive Intelligence Brief. https://druglandscape.com/ci/ak117. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab